UNITED THERAPEUTICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 281.9 USD | +2.21% |
|
+1.85% | +28.18% |
| Sales 2024 * | 2.74B 3.76B | Sales 2025 * | 2.97B 4.08B | Capitalization | 12.51B 17.19B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.19B 1.63B | Net income 2025 * | 1.29B 1.78B | EV / Sales 2024 * | 3.77 x |
| Net cash position 2024 * | 2.19B 3.01B | Net cash position 2025 * | 3.95B 5.43B | EV / Sales 2025 * | 2.89 x |
| P/E ratio 2024 * |
11.5
x | P/E ratio 2025 * |
10.5
x | Employees | 1,168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.63% |
More Fundamentals
* Assessed data
More news
Latest transcript on United Therapeutics Corporation
More recommendations
More press releases
More news
| 1 day | +2.21% | ||
| 1 week | +1.85% | ||
| Current month | +2.45% | ||
| 1 month | +6.66% | ||
| 3 months | +14.17% | ||
| 6 months | +11.98% | ||
| Current year | +28.18% |
1 week
269.59
283.20
1 month
264.33283.20
Current year
208.62283.20
1 year
208.62283.20
3 years
158.38283.20
5 years
74.31283.20
10 years
74.31283.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 69 | 96-06-25 | |
| President | 52 | 11-03-31 | |
James Edgemond
DFI | Director of Finance/CFO | 56 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Raymond Kurzweil
BRD | Director/Board Member | 76 | 01-12-31 |
| Chief Executive Officer | 69 | 96-06-25 | |
Tommy Thompson
BRD | Director/Board Member | 81 | 09-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.06% | 1 M€ | +0.84% | - | |
| 2.87% | 2 M€ | +9.20% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-12 | 281.9 | +2.21% | 506,293 |
| 24-06-11 | 275.8 | +0.19% | 599,758 |
| 24-06-10 | 275.2 | +0.09% | 1,045,119 |
| 24-06-07 | 275 | -0.51% | 505,301 |
| 24-06-06 | 276.4 | -0.12% | 456,809 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm
More quotes
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
Calendar
2024-06-25
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
281.9
USD
Average target price
295.9
USD
Spread / Average Target
+5.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.18% | 12.51B | |
| +48.54% | 56.61B | |
| +36.70% | 39.25B | |
| -6.02% | 39.62B | |
| -6.90% | 28.28B | |
| +12.97% | 26.44B | |
| -16.91% | 20.12B | |
| +31.71% | 12.48B | |
| +0.38% | 12.2B | |
| -9.54% | 11.02B |
- Stock Market
- Equities
- UTHR Stock
